Xencor (XNCR) Change in Account Payables (2013 - 2026)
Xencor (XNCR) reported Change in Account Payables of -$2.9 million for Q1 2026, down 405.46% year-over-year from $939900.9 in Q1 2025, and down 269.78% quarter-over-quarter from $1.7 million in Q4 2025.
Xencor (XNCR) Change in Account Payables (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Change in Account Payables data on file, last reported at -$2.9 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at -$2.9 million, down 405.46% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.3 million (down 3575.56% YoY), and the FY2025 annual result was -$4.0 million, down 238.95% from the prior year.
- Change in Account Payables declined to -$2.9 million in Q1 2026 per XNCR's latest filing, from $1.7 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $5.3 million in Q1 2023 and troughed at -$9.5 million in Q3 2025.
- A 5-year average of -$239176.5 and a median of -$568000.0 in 2025 frame the typical range for Change in Account Payables.
- On a YoY basis, Change in Account Payables climbed as much as 2630.64% in 2025 and fell as far as 422.44% in 2025.
- A 5-year view of Change in Account Payables shows it stood at -$4.5 million in 2022, then soared by 76.75% to -$1.1 million in 2023, then plunged by 90.98% to -$2.0 million in 2024, then jumped by 184.09% to $1.7 million in 2025, then slumped by 269.78% to -$2.9 million in 2026.
- Business Quant data shows XNCR's Change in Account Payables at -$2.9 million in Q1 2026, $1.7 million in Q4 2025, and -$9.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | -2.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.87 Mn |
| Mar 31, 2026 | -2.87 Mn |
| Dec 31, 2025 | 1.69 Mn |
| Dec 31, 2025 | 1.69 Mn |
| Sep 30, 2025 | -9.45 Mn |
| Sep 30, 2025 | -9.45 Mn |
| Jun 30, 2025 | 4.38 Mn |
| Jun 30, 2025 | 4.38 Mn |
| Mar 31, 2025 | -568,000.00 |
| Mar 31, 2025 | -568,000.00 |
| Dec 31, 2024 | -2.01 Mn |
| Dec 31, 2024 | -2.01 Mn |
| Sep 30, 2024 | 2.93 Mn |
| Sep 30, 2024 | 2.93 Mn |
| Jun 30, 2024 | -173,000.00 |
| Jun 30, 2024 | -173,000.00 |
| Mar 31, 2024 | 2.10 Mn |
| Mar 31, 2024 | 2.10 Mn |
| Dec 31, 2023 | -1.05 Mn |
| Dec 31, 2023 | -1.05 Mn |